Speke Resort & Conference Centre Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2012



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Drug Resistance and Persistence in Tuberculosis (E1)


Organizer(s) Ann M. Ginsberg and John D. McKinney
May 13—18, 2012
Speke Resort & Conference Centre • Kampala, Uganda
Abstract Deadline: Jan 13, 2012
Late Abstract Deadline: Feb 14, 2012
Scholarship Deadline: Jan 13, 2012
Early Registration Deadline: Mar 16, 2012

Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation. Sponsored by GlaxoSmithKline

Summary of Meeting:
According to the World Health Organization, over 25% of new tuberculosis cases in some subnational regions are multi-drug-resistant TB (MDR-TB) and, as of March 2010, 58 countries had reported XDR-TB (TB resistant to the major classes of both first- and second-line drugs). The Keystone Symposia meeting on Drug Resistance and Persistence in Tuberculosis aims to bring together basic and clinical researchers and public health experts from diverse backgrounds to explore the following: 1) the fundamental biology underlying genetic and phenotypic drug-resistance in TB; 2) progress in expanding capacity in high-burden settings to perform drug susceptibility testing; 3) identification of novel drug targets; 4) innovative strategies for drug discovery; and 5) advances in developing multi-drug regimens that will be effective against currently drug-resistant as well as drug-sensitive strains of M. tuberculosis. Investigators from outside the TB field will be included to provide new perspectives and stimulate fresh approaches for tackling this global public health priority.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, MAY 13

15:00—19:30
Registration

Speke Lobby
18:15—19:15
Refreshments

Calabash Lounge
19:15—20:30
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Commonwealth Ballroom
* Ann M. Ginsberg, Aeras, USA

Virander Singh Chauhan, International Centre for Genetic Engineering and Biotechnology, India
MDR TB: How to Deal with a Major Global Health Challenge?


MONDAY, MAY 14

08:00—09:00
Breakfast

Nyanja Restaurant
08:00—09:00
Poster Setup

Commonwealth Ballroom
09:00—17:00
Poster Viewing

Commonwealth Ballroom
09:00—12:15
Mechanisms of Drug Resistance (Including Lessons from Other Fields)
Meeting has ended...abstracts no longer viewable online.

Commonwealth Ballroom
* Eric J. Rubin, Harvard School of Public Health, USA

Valerie Mizrahi, University of Cape Town, South Africa
Mechanisms Driving Mutations to Drug Resistance

Adam C. Palmer, Harvard Medical School, USA
Drug Interactions and Evolution of Drug Resistance

Sébastien Gagneux, Swiss Tropical and Public Health Institute, Switzerland
The Fitness Cost of Drug Resistance

Moses Joloba, Makerere University, Uganda
MDR and XDR Strains

Vikram Saini, University of Alabama, Birmingham, USA
Short Talk: Next-Generation Sequencing and Analysis of Cigarette Smoke-Induced Drug Resistant Mycobacterium tuberculosis Strains: Discovery of a Cigarette Smoke Signature

Nataly Alvarez, Corporation for Biological Research, Colombia
Short Talk: The Structural Modeling of the Interaction between Levofloxacin and the Mycobacterium tuberculosis Gyrase Catalytic Site Sheds Light on the Mechanisms of Fluoroquinolones Resistant tuberculosis in Colombian Clinical Isolates

10:20—10:40
Coffee Break

Calabash Lounge
12:15—13:00
Lunch

Nyanja Restaurant
13:00—15:30
Poster Session 1

Commonwealth Ballroom
15:30—16:00
Coffee Available

Calabash Lounge
16:00—18:00
Future of the MDR/XDR Epidemic: Progress in Diagnosis of Drug-Resistant TB
Meeting has ended...abstracts no longer viewable online.

Commonwealth Ballroom
* David Alland, Rutgers University - NJMS, USA

Megan Murray, Harvard Medical School, USA
Approaches to Understanding the Epidemic Dynamics of Drug Resistant TB

Chris Gilpin, World Health Organization, Switzerland
The Global Laboratory Initiative: Needs and Progress in Laboratory Infrastructure

Philippe Jacon, FIND (Foundation for Innovative New Diagnostics), Switzerland
Progress in Developing Point-of-Treatment Methods for Drug Susceptibility Testing: What’s on the Horizon?

David Alland, Rutgers University - NJMS, USA

18:00
On Own for Dinner


TUESDAY, MAY 15

08:00—09:00
Breakfast

Nyanja Restaurant
09:00—12:00
Persistence (Phenotypic Drug Resistance) - Including Examples from Other Fields
Meeting has ended...abstracts no longer viewable online.

Commonwealth Ballroom
* Valerie Mizrahi, University of Cape Town, South Africa

John D. McKinney, Swiss Federal Institute of Technology (EPFL), Switzerland
Individuality of Bacterial Responses to Antibiotics

X. Sunney Xie, Harvard University, USA
Persistence in Escherichia coli

Natalie Balaban, Hebrew University, Israel
Noise Amplification and Persistence

Brian Weinrick, HHMI/Albert Einstein College of Medicine, USA
Short Talk: A Persistence-Enhancing Transcriptional Program Coordinated by whiB6

Heather L. Torrey, Northeastern University, USA
Short Talk: Analysis of High-Persister Strains in Mycobacterium tuberculosis

Cyrielle I. Kint, University of Leuven, Belgium
Short Talk: Structure-Function Analysis of an Essential GTPase Involved in Bacterial Persistence

Veerle R. Liebens, University of Leuven, Belgium
Short Talk: New Insight into an Old Phenomenon: Extracellular Properties Determine Fluoroquinolone Tolerance in Pseudomonas aeruginosa

10:20—10:40
Coffee Break

Calabash Lounge
12:00—13:00
Poster Setup

Commonwealth Ballroom
12:00
On Own for Lunch and Recreation

13:00—22:00
Poster Viewing

Commonwealth Ballroom
16:30—17:00
Coffee Available

Calabash Lounge
17:00—19:00
Progress in TB Drug Discovery
Meeting has ended...abstracts no longer viewable online.

Commonwealth Ballroom
* Zhenkun Ma, Global Alliance for TB Drug Development, USA

Eric J. Rubin, Harvard School of Public Health, USA
Overview of Current and Future Approaches to TB Drug Discovery

Oren Zimhony, Kaplan Medical Center affiliated to the school of Medicine Hebrew Universit, Israel
The Challenge of Pyrazinamide: Dissecting "Mechanism" between Sterilizing Effect, Conditions for Susceptibility and Site of Action

David Barros, GlaxoSmithKline / DDDW, Spain
TB Drug Discovery at GSK

Claude Kirimuhuzya, Kampala International University-Western Campus, Uganda
Short Talk: Eficacy of Uganda’s Plants on Rifampicin-Resistant Tuberculosis: A Review of Research Done in Uganda since 2006

19:00—20:00
Social Hour with Lite Bites

Nyanja Restaurant
19:30—22:00
Poster Session 2

Commonwealth Ballroom

WEDNESDAY, MAY 16

08:00—09:00
Breakfast

Nyanja Restaurant
08:00—09:00
Poster Setup

Commonwealth Ballroom
09:00—17:00
Poster Viewing

Commonwealth Ballroom
09:00—12:00
Novel Approaches to TB Drug Discovery
Meeting has ended...abstracts no longer viewable online.

Commonwealth Ballroom
* Ann M. Ginsberg, Aeras, USA

Gilla Kaplan, Bill & Melinda Gates Foundation, USA
Immunomodulatory Molecules as Adjuvant Chemotherapy for TB

Kanury V. S. Rao, International Centre for Genetic Engineering and Biotechnology, India
Elucidating the Crosstalk Mechanisms that Facilitate Intra-Macrophage Survival of Mycobacterium tuberculosis

Priscille Marie Brodin, CIIL Institut Pasteur, France
High Content Screening of M. tuberculosis Infected Macrophage as a Pre-Clinical Model for the Development of Novel Anti-Tuberculosis Drug Candidates

John Szumowski, University of Washington, USA
Macrophage-Induced, Bacterial Efflux Pump-Mediated Drug Tolerance in Tuberculosis

Melanie Grobbelaar, University of Stellenbosch Faculty of Health Sciences, South Africa
Short Talk: Adaptation of the Mycobacterium tuberculosis Transcriptome in Response to Rifampicin

10:20—10:40
Coffee Break

Calabash Lounge
12:00—13:00
Lunch

Nyanja Restaurant
13:00—15:30
Poster Session 3

Commonwealth Ballroom
15:30—16:00
Coffee Available

Calabash Lounge
16:00—18:00
Novel Drug Targets
Meeting has ended...abstracts no longer viewable online.

Commonwealth Ballroom
* Lawrence Geiter, Otsuka Pharmaceutical Development and Commercialization Inc., USA

Zhenkun Ma, Global Alliance for TB Drug Development, USA
Target-Based Approach in Tuberculosis Drug Discovery

Graham F. Hatfull, University of Pittsburgh, USA
Exploration and Exploitation of Mycobacteriophages

Katarina Mikusova, Comenius University, Faculty of Natural Sciences, Slovakia
DprE1 – Past, Present and Future

Yap J. B. Boum II, Epicentre Mbarara Research Base, Uganda
Short Talk: Thymidylate Synthase ThyX: An Excellent Target for New Anti-Tuberculosis Drugs

18:00
On Own for Dinner


THURSDAY, MAY 17

08:00—09:00
Breakfast

Nyanja Restaurant
09:00—12:00
Updates on Progress in Developing Novel TB Treatments for M(X)XDR-TB
Meeting has ended...abstracts no longer viewable online.

Commonwealth Ballroom
* Moses Joloba, Makerere University, Uganda

Myriam Haxaire, Tibotec BVBA, Belgium
TMC207 Clinical Development Status

Lawrence Geiter, Otsuka Pharmaceutical Development and Commercialization Inc., USA
Clinical Development of Delamanid (OPC-67683)

Daniel E. Everitt, TB Alliance, USA
Unified DS/DR Development Pathway for Novel TB Drug Regimens

Derek J. Sloan, Malawi Liverpool Wellcome Trust Clinical Research Programme, Malawi
Short Talk: Bacillary Elimination Rates, Persister Phenotypes and Clinical Outcomes in a Longitudinal Study of TB Treatment in Malawi

Umesh D. Gupta, National Jalma Institute for Leprosy and Other Mycobacterial Diseases, India
Short Talk: Mycobacterium indicus pranii as a Stand-Alone or Adjunct Immunotherapeutic in Treatment of Experimental Animal Tuberculosis

Ann M. Ginsberg, Aeras, USA
The Ultimate Weapon Against Resistance and Persistence: Progress in Development of New TB Vaccines

10:20—10:40
Coffee Break

Calabash Lounge
12:00
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Calabash Lounge
17:00—19:00
Late-Breaking Session
Meeting has ended...abstracts no longer viewable online.

Commonwealth Ballroom
* John D. McKinney, Swiss Federal Institute of Technology (EPFL), Switzerland

Sarah M. Fortune, Harvard School of Public Health, USA
Mutation Rate/Evolution of Drug Resistance Project

Mike R. Barer, University of Leicester, UK
Evidence for Persistent Bacteria in Sputa of Antibiotic-Treated TB Patients

Pierre Ankomah, Emory University, USA
Short Talk: Two-Drug Antimicrobial Chemotherapy: A Mathematical Model and Experiments with Mycobacterium marinum

Juan Manuel Belardinelli, Colorado State University, USA
Short Talk: Mutations in the beta-Hydroxyacyl ACP Dehydratase Confer Resistance to Thiacetazone in M. tuberculosis and M. kansasii

Elizabeth Maria Streicher, Stellenbosch University, South Africa
Short Talk: Mycobacterium tuberculosis Population Structure Determines the Outcome of Genetic Based Second-Line Drug Resistance Testing

19:00—20:00
Social Hour with Lite Bites

Poolside Lawn
20:00—23:00
Entertainment

Poolside Lawn

FRIDAY, MAY 18

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Bill & Melinda Gates Foundation GlaxoSmithKline

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AI098285-01

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional support for this conference from:

Hain Lifescience GmbH

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



GlaxoSmithKline / DDDW


Tibotec BVBA


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676